The discovery of new anesthetics by targeting GABAA receptors

Expert Opinion on Drug Discovery

Volumn 6, Issue 11, 2011, Pages 1187-1201

  Krasowski, Matthew D ^a   Hopfinger, Anton J ^b,c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c Chem21 Group Inc   (United States)

Author keywords

ADMET; anesthetics; GABA receptors; structure based design

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALFAXALONE; ANESTHETIC AGENT; AZD 3043; CARBOETOMIDATE; CHLORALOSE; DESFLURANE; ETOMIDATE; FOSPROPOFOL; ISOFLURANE; METHOHEXITAL; METHOXYCARBONYLETOMIDATE; PF 0713; PROPOFOL; PROPRANIDID; SEVOFLURANE; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; GENERAL ANESTHESIA; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

EID: 80755130606     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.627324     Document Type: Review

References (138)

1. Kopp Lugli A, Yost CS, Kindler CH. Anaesthetic mechanisms: update on the challenge of unravelling the mystery of anaesthesia. Eur J Anaesthesiol 2009;26:807-20
2. Franks NP, Lieb WR. Where do general anaesthetics act? Nature 1978;274:339-42
3. Franks NP, Lieb WR. Which molecular targets are most relevant to general anaesthesia? Toxicol Lett 1998;100-101:1-8 (Pubitemid 29069121)
4. Garcia PS, Kolesky SE, Jenkins A. General anesthetic actions on GABAA receptors. Curr Neuropharmacol 2010;8:2-9
5. Krasowski MD. Contradicting a unitary theory of general anesthetic action: a history of three compounds from 1901 to 2001. Bull Anesth Hist 2003;21:1; 4-8, 21 passim
6. Krasowski MD, Harrison NL. General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci 1999;55:1278-303 (Pubitemid 29410747)
7. Forman SA, Miller KW. Anesthetic sites and allosteric mechanisms of action on Cys-loop ligand-gated ion channels. Can J Anaesth 2011;58:191-205
8. Franks NP. Molecular targets underlying general anaesthesia. Br J Pharmacol 2006;147(Suppl 1):S72-81 (Pubitemid 43077264)
9. Franks NP. General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci 2008;9:370-86 (Pubitemid 351556044)
10. Hanson SM, Czajkowski C. Structural mechanisms underlying benzodiazepine modulation of the GABAA receptor. J Neurosci 2008;28:3490-9 (Pubitemid 351469312)
11. Sigel E. Mapping of the benzodiazepine recognition site on GABAA receptors. Curr Top Med Chem 2002;2:833-9
12. Ortells MO, Lunt GG. Evolutionary history of the ligand-gated ion-channel superfamily of receptors. Trends Neurosci 1995;18:121-7
13. Gruss M, Bushell TJ, Bright DP, et al. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 2004;65:443-52 (Pubitemid 38134273)
14. Cherubini E, Gaiarsa JL, Ben-Ari Y. GABA: an excitatory transmitter in early postnatal life. Trends Neurosci 1991;14:515-19
15. Forman SA. Molecular approaches to improving general anesthetics. Anesthesiol Clin 2010;28:761-71
16. McCormick DA. GABA as an inhibitory neurotransmitter in human cerebral cortex. J Neurophysiol 1989;62:1018-27 (Pubitemid 19278424)
17. Cossart R, Bernard C, Ben-Ari Y. Multiple facets of GABAergic neurons and synapses: multiple fates of GABA signalling in epilepsies. Trends Neurosci 2005;28:108-15 (Pubitemid 40178928)
18. Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 2008;60:243-60
19. Chang Y, Wang R, Barot S, Weiss DS. Stoichiometry of a recombinant GABAA receptor. J Neurosci 1996;16:5415-24
20. McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 1996;19:139-43
21. Bonin RP, Orser BA. GABAA receptor subtypes underlying general anesthesia. Pharmacol Biochem Behav 2008;90:105-12
22. Da Settimo F, Taliani S, Trincavelli ML, et al. GABA A/Bz receptor subtypes as targets for selective drugs. Curr Med Chem 2007;14:2680-701 (Pubitemid 350048323)
23. Mirza NR, Munro G. The role of GABAA receptor subtypes as analgesic targets. Drug News Perspect 2010;23:351-60
24. Reynolds DS. The value of genetic and pharmacological approaches to understanding the complexities of GABAA receptor subtype functions: the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 2008;90:37-42
25. Belelli D, Lambert JJ, Peters JA, et al. The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid. Proc Natl Acad Sci USA 1997;94:11031-6
26. Uchida I, Kamatchi G, Burt D, Yang J.Etomidate potentiation of GABAA receptor gated current depends on the subunit composition. Neurosci Lett 1995;185:203-6
27. Krasowski MD, O'Shea SM, Rick CE, et al. alpha subunit isoform influences GABAA receptor modulation by propofol. Neuropharmacology 1997;36:941-9 (Pubitemid 27300124)
28. Bovill JG. Inhalation anaesthesia: from diethyl ether to xenon. Handb Exp Pharmacol 2008;182:121-42
29. Terrell RC. The invention and development of enflurane, isoflurane, sevoflurane, and desflurane. Anesthesiology 2008;108:531-3
30. Newman S, Stygall J, Hirani S, et al. Postoperative cognitive dysfunction after noncardiac surgery: a systematic review. Anesthesiology 2007;106:572-90 (Pubitemid 46662224)
31. Selnes OA, Grega MA, Bailey MM, et al. Cognition 6 years after surgical or medical therapy for coronary artery disease. Ann Neurol 2008;63:581-90
32. Istaphanous GK, Loepke AW. General anesthetics and the developing brain. Curr Opin Anaesthesiol 2009;22:368-73
33. Lee TA, Wolozin B, Weiss KB, Bednar MM. Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J Alzheimers Dis 2005;7:319-24 (Pubitemid 41206944)
34. Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003;348:2110-24 (Pubitemid 36583307)
35. Krasowski MD. Differential modulatory actions of the volatile convulsant flurothyl and its anesthetic isomer at inhibitory ligand-gated ion channels. Neuropharmacology 2000;39:1168-83 (Pubitemid 30173182)
36. Krasowski MD, Harrison NL. The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations. Br J Pharmacol 2000;129:731-43 (Pubitemid 30153857)
37. Mihic SJ, Ye Q, Wick MJ, et al. Sites of alcohol and volatile anaesthetic action on GABAA and glycine receptors. Nature 1997;389:385-9 (Pubitemid 27415220)
38. Nishikawa K, Harrison NL. The actions of sevoflurane and desflurane on the gamma-aminobutyric acid receptor type A: effects of TM2 mutations in the alpha and beta subunits. Anesthesiology 2003;99:678-84 (Pubitemid 37051984)
39. Rau V, Iyer SV, Oh I, et al. gamma-aminobutyric acid type A receptor alpha4 subunit knockout mice are resistant to the amnestic effect of isoflurane. Anesth Analg 2009;109:1816-22
40. Sonner JM, Werner DF, Elsen FP, et al. Effect of isoflurane and other potent inhaled anesthetics on minimum alveolar concentration, learning, and the righting reflex in mice engineered to express alpha1 gamma-aminobutyric acid type A receptors unresponsive to isoflurane. Anesthesiology 2007;106:107-13 (Pubitemid 46035410)
41. Werner DF, Swihart A, Rau V, et al. Inhaled anesthetic responses of recombinant receptors and knockin mice harboring alpha2(S270H/L277A) GABAA receptor subunits that are resistant to isoflurane. J Pharmacol Exp Ther 2011;336:134-44
42. Gruss M, Mathie A, Lieb WR, Franks NP. The two-pore-domain K+ channels TREK-1 and TASK-3 are differentially modulated by copper and zinc. Mol Pharmacol 2004;66:530-7 (Pubitemid 39329251)
43. Vanlersberghe C, Camu F. Propofol. Handb Exp Pharmacol 2008;182:227-52
44. Shafer SL. Propofol formulations. Semin Anesth 2002;214:248-57 (Pubitemid 36109153)
45. Trapani G, Altomare C, Liso G, et al. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem 2000;7:249-71 (Pubitemid 30396448)
46. Krasowski MD, Koltchine VV, Rick CE, et al. Propofol and other intravenous anesthetics have sites of action on the gamma-aminobutyric acid type A receptor distinct from that for isoflurane. Mol Pharmacol 1998;53:530-8 (Pubitemid 28162877)
47. Nishikawa K, Jenkins A, Paraskevakis I, Harrison NL. Volatile anesthetic actions on the GABAA receptors: contrasting effects of alpha1(S270) and beta2(N265) point mutations. Neuropharmacology 2002;42:337-45 (Pubitemid 34230486)
48. Bali M, Akabas MH. Defining the propofol binding site location on the GABAA receptor. Mol Pharmacol 2004;65:68-76 (Pubitemid 38113887)
49. Krasowski MD, Hong X, Hopfinger AJ, Harrison NL. 4D-QSAR analysis of a set of propofol analogues: mapping binding sites for an anesthetic phenol on the GABAA receptor. J Med Chem 2002;45:3210-21 (Pubitemid 34774272)
50. Krasowski MD, Jenkins A, Flood P, et al. General anesthetic potencies of a series of propofol analogs correlate with potency for potentiation of gamma-aminobutyric acid (GABA) current at the GABAA receptor but not with lipid solubility. J Pharmacol Exp Ther 2001;297:338-51 (Pubitemid 32242594)
51. Krasowski MD, Nishikawa K, Nikolaeva N, et al. Methionine 286 in transmembrane domain 3 of the GABAA receptor beta subunit controls a binding cavity for propofol and other alkylphenol general anesthetics. Neuropharmacology 2001;41:952-64 (Pubitemid 34024991)
52. Hall MA, Xi J, Lor C, et al. m-Azipropofol (AziPm) a photoactive analogue of the intravenous general anesthetic propofol. J Med Chem 2010;53:5667-75
53. Campion ME, Gan TJ. Fospropofol disodium for sedation. Drugs Today (Barc) 2009;45:567-76
54. Garnock-Jones KP, Scott LJ. Fospropofol. Drugs 2010;70:469-77
55. Banaszczyk MG, Carlo AT, Millan V, et al. Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. Anesth Analg 2002;95:1285-92; table of contents (Pubitemid 35239126)
56. Harris EA, Lubarsky DA, Candiotti KA. Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol. Ther Clin Risk Manag 2009;5:949-59
57. Krasowski MD. GPI-15715 Guilford. Curr Opin Investig Drugs 2005;6:90-8
58. Lingamaneni R, Krasowski MD, Jenkins A, et al. Anesthetic properties of 4-iodopropofol: implications for mechanisms of anesthesia. Anesthesiology 2001;94:1050-7 (Pubitemid 32506134)
59. Sanna E, Motzo C, Usala M, et al. Characterization of the electrophysiological and pharmacological effects of 4-iodo-2,6- diisopropylphenol, a propofol analogue devoid of sedative-anaesthetic properties. Br J Pharmacol 1999;126:1444-54 (Pubitemid 29142076)
60. Trapani G, Latrofa A, Franco M, et al. Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological profile at recombinant human GABAA receptors. J Med Chem 1998;41:1846-54 (Pubitemid 28248660)
61. Peters JA, Lambert JJ, Cottrell GA. An electrophysiological investigation of the characteristics and function of GABAA receptors on bovine adrenomedullary chromaffin cells. Pflugers Arch 1989;415:95-103 (Pubitemid 19257334)
62. Egan TD, Shafer SL, Jenkins TE, et al. The pharmacokinetics and pharmacodynamics of THRX-918661, a novel sedative/ hypnotic agent [abstract]. Anesthesiology 2003;99:A516
63. Sneyd JR. Recent advances in intravenous anaesthesia. Br J Anaesth 2004;93:725-36 (Pubitemid 39445555)
64. Ahrens J, Leuwer M, de la Roche J, et al. The non-anaesthetic propofol analogue 2,6-di-tert-butylphenol fails to modulate GABAA receptor function. Pharmacology 2009;83:95-8
65. James R, Glen JB. Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents. J Med Chem 1980;23:1350-7 (Pubitemid 11164104)
66. Ya Deau JT, Heerdt PM, The AH, Wang Q. Hemodynamic effects of di-sec-butyl phenol, an anesthetic substituted phenol. Pharmacology 2006;76:117-22 (Pubitemid 43289463)
67. Siegel LC, Konstantatos A. PF0713 produced rapid induction of general anesthesia without injection pain in a phase 1 study [abstract]. Anesthesiology 2009;111:A4643
68. Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology 2011;114:695-707
69. Godefroi EF, Janssen PA, Vandereycken CA, et al. Dl-1-(1- Arylalkyl)Imidazole-5-Carboxylate Esters. A Novel Type of Hypnotic Agents. J Med Chem 1965;8:220-3
70. Bloomfield R, Noble DW. Etomidate and fatal outcome-even a single bolus dose may be detrimental for some patients. Br J Anaesth 2006;97:116-17
71. Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984;61:647-51 (Pubitemid 15223411)
72. Cirone J, Rosahl TW, Reynolds DS, et al. gamma-aminobutyric acid type A receptor beta2 subunit mediates the hypothermic effect of etomidate in mice. Anesthesiology 2004;100:1438-45 (Pubitemid 38679313)
73. O'Meara GF, Newman RJ, Fradley RL, et al. The GABAA beta3 subunit mediates anaesthesia induced by etomidate. Neuroreport 2004;15:1653-6 (Pubitemid 38971188)
74. Reynolds DS, Rosahl TW, Cirone J, et al. Sedation and anesthesia mediated by distinct GABAA receptor isoforms. J Neurosci 2003;23:8608-17 (Pubitemid 37158760)
75. Zeller A, Arras M, Jurd R, Rudolph U. Identification of a molecular target mediating the general anesthetic actions of pentobarbital. Mol Pharmacol 2007;71:852-9 (Pubitemid 46294097)
76. Zeller A, Arras M, Lazaris A, et al. Distinct molecular targets for the central respiratory and cardiac actions of the general anesthetics etomidate and propofol. FASEB J 2005;19:1677-9 (Pubitemid 41429527)
77. Martin LJ, Oh GH, Orser BA. Etomidate targets a5 gammaaminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology 2009;111:1025-35
78. Dorr HG, Kuhnle U, Holthausen H, et al. Etomidate: a selective adrenocortical 11 beta-hydroxylase inhibitor. Klin Wochenschr 1984;62:1011-13 (Pubitemid 14017346)
79. Roumen L, Sanders MP, Pieterse K, et al. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. J Comput Aided Mol Des 2007;21:455-71 (Pubitemid 47423278)
80. Cotten JF, Forman SA, Laha JK, et al. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010;112:637-44
81. Cotten JF, Ge RL, Banacos N, et al. Closed-loop continuous infusions of etomidate and etomidate analogs in rats: a comparative study of dosing and the impact on adrenocortical function. Anesthesiology 2011; In press
82. Cotten JF, Husain SS, Forman SA, et al. Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009;111:240-9
83. Al-Nadaf A, Abu Sheikha G, Taha MO. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads. Bioorg Med Chem 2010;18:3088-115
84. Dubrovsky BO. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:169-92
85. Harrison NL, Majewska MD, Harrington JW, Barker JL. Structure-activity relationships for steroid interaction with the gamma-aminobutyric acidA receptor complex. J Pharmacol Exp Ther 1987;241:346-53 (Pubitemid 17119381)
86. Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 2006;444:486-9 (Pubitemid 44809065)
87. Li GD, Chiara DC, Cohen JB, Olsen RW. Neurosteroids allosterically modulate binding of the anesthetic etomidate to gamma-aminobutyric acidtype A receptors. J Biol Chem 2009;284:11771-5
88. Mitchell EA, Herd MB, Gunn BG, et al. Neurosteroid modulation of GABAA receptors: molecular determinants and significance in health and disease. Neurochem Int 2008;52:588-95 (Pubitemid 351146675)
89. Dildy-Mayfield JE, Mihic SJ, Liu Y, et al. Actions of long chain alcohols on GABAA and glutamate receptors: relation to in vivo effects. Br J Pharmacol 1996;118:378-84
90. Krasowski MD, Finn SE, Ye Q, Harrison NL. Trichloroethanol modulation of recombinant GABAA, glycine and GABA r1 receptors. J Pharmacol Exp Ther 1998;284:934-42 (Pubitemid 28130820)
91. Lovinger DM, Zimmerman SA, Levitin M, et al. Trichloroethanol potentiates synaptic transmission mediated by gamma-aminobutyric acidA receptors in hippocampal neurons. J Pharmacol Exp Ther 1993;264:1097-103 (Pubitemid 23318599)
92. Peoples RW, Weight FF. Trichloroethanol potentiation of gamma-aminobutyric acid-activatedchloride current in mouse hippocampal neurones. Br J Pharmacol 1994;113:555-63
93. Garrett KM, Gan J. Enhancement of gamma-aminobutyric acidA receptor activity by alpha-chloralose. J Pharmacol Exp Ther 1998;285:680-6 (Pubitemid 28237448)
94. Ishizuka S, Sikdar SK, Yasui S, et al. alpha-chloralose opens the chloride channel of frog isolated sensory neurons. Brain Res 1989;498:181-4 (Pubitemid 19228180)
95. Beydoun A, D'Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9:33-42
96. Perucca E, Yasothan U, Clincke G, Kirkpatrick P. Lacosamide. Nat Rev Drug Discov 2008;7:973-4
97. Chisari M, Eisenman LN, Covey DF, et al. The sticky issue of neurosteroids and GABAA receptors. Trends Neurosci 2010;33:299-306
98. Mellon SH, Griffin LD. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 2002;13:35-43 (Pubitemid 36734014)
99. Akk G, Covey DF, Evers AS, et al. Mechanisms of neurosteroid interactions with GABAA receptors. Pharmacol Ther 2007;116:35-57 (Pubitemid 47391029)
100. Covey DF, Evers AS, Mennerick S, et al. Recent developments in structure-activity relationships for steroid modulators of GABAA receptors. Brain Res Brain Res Rev 2001;37:91-7 (Pubitemid 34020723)
101. Hosie AM, Clarke L, da Silva H, Smart TG. Conserved site for neurosteroid modulation of GABAA receptors. Neuropharmacology 2009;56:149-54
102. Hosie AM, Wilkins ME, Smart TG. Neurosteroid binding sites on GABAA receptors. Pharmacol Ther 2007;116:7-19 (Pubitemid 47398919)
103. Veleiro AS, Burton G. Structure-activity relationships of neuroactive steroids acting on the GABAA receptor. Curr Med Chem 2009;16:455-72
104. Jager AK, Saaby L. Flavonoids and the CNS. Molecules 2011;16:1471-85
105. Johnston GA, Hanrahan JR, Chebib M, et al. Modulation of ionotropic GABA receptors by natural products of plant origin. Adv Pharmacol 2006;54:285-316
106. Hanrahan JR, Chebib M, Johnston GA. Flavonoid modulation of GABAA receptors. Br J Pharmacol 2011;163:234-45
107. Hevers W, Hadley SH, Luddens H, Amin J. Ketamine, but not phencyclidine, selectively modulates cerebellar GABAA receptors containing alpha6 and delta subunits. J Neurosci 2008;28:5383-93
108. Irifune M, Sato T, Kamata Y, et al. Evidence for GABAA receptor agonistic properties of ketamine: convulsive and anesthetic behavioral models in mice. Anesth Analg 2000;91:230-6 (Pubitemid 30437092)
109. Venkatarangan P, Hopfinger AJ. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase. J Med Chem 1999;42:2169-79 (Pubitemid 29284236)
110. Downes H, Courogen PM. Contrasting effects of anesthetics in tadpole bioassays. J Pharmacol Exp Ther 1996;278:284-96 (Pubitemid 27167106)
111. Picard R, Cook D. Cross-validation of regression models. J Am Stat Assoc 1984;79:575-83
112. Bocquet N, Prado de Carvalho L, Cartaud J, et al. A prokaryotic proton-gated ion channel from the nicotinic acetylcholine receptor family. Nature 2007;445:116-19 (Pubitemid 46067312)
113. Weng Y, Yang L, Corringer PJ, Sonner JM. Anesthetic sensitivity of the Gloeobacter violaceus proton-gated ion channel. Anesth Analg 2010;110:59-63
114. Bocquet N, Nury H, Baaden M, et al. X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. Nature 2009;457:111-14
115. Hilf RJ, Dutzler R. Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel. Nature 2009;457:115-18
116. Nury H, Van Renterghem C, Weng Y, et al. X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature 2011;469:428-31
117. Speranskiy K, Cascio M, Kurnikova M. Homology modeling and molecular dynamics simulations of the glycine receptor ligand binding domain. Proteins 2007;67:950-60 (Pubitemid 46753942)
118. Haile JM. Molecular dynamics simulation: elementary methods. Hoboken, NJ: John Wiley & Sons; 1997
119. Cheng J, Ju XL. Homology modeling and atomic level binding study of GABAA receptor with novel enaminone amides. Eur J Med Chem 2010;45:3595-600
120. Bali M, Jansen M, Akabas MH. GABA-induced intersubunit conformational movement in the GABAA receptor alpha1M1-beta2M3 transmembrane subunit interface: experimental basis for homology modeling of an intravenous anesthetic binding site. J Neurosci 2009;29:3083-92
121. Trudell JR, Yue ME, Bertaccini EJ, et al. Molecular modeling and mutagenesis reveals a tetradentate binding site for Zn2+ in GABAA alphabeta receptors and provides a structural basis for the modulating effect of the gamma subunit. J Chem Inf Model 2008;48:344-9 (Pubitemid 351473037)
122. Zhu F, Hummer G. Gating transition of pentameric ligand-gated ion channels. Biophys J 2009;97:2456-63
123. Bhattacharya AA, Curry S, Franks NP. Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J Biol Chem 2000;275:38731-8 (Pubitemid 32009208)
124. Deeb O, Rosales-Hernandez MC, Gomez-Castro C, et al. Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions. Biopolymers 2010;93:161-70
125. Zsila F, Bikadi Z, Malik D, et al. Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking. Bioinformatics 2011;27:1806-13
126. Vedula LS, Brannigan G, Economou NJ, et al. A unitary anesthetic binding site at high resolution. J Biol Chem 2009;284:24176-84
127. Butts CA, Xi J, Brannigan G, et al. Identification of a fluorescent general anesthetic, 1-aminoanthracene. Proc Natl Acad Sci USA 2009;106:6501-6
128. Lea WA, Xi J, Jadhav A, et al. A high-throughput approach for identification of novel general anesthetics. PLoS ONE 2009;4:e7150
129. Eckenhoff R, Zheng W, Kelz M. From anesthetic mechanisms research to drug discovery. Clin Pharmacol Ther 2008;84:144-8 (Pubitemid 351861506)
130. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 1999;88:815-21 (Pubitemid 29398551)
131. Iyer M, Mishru R, Han Y, Hopfinger AJ. Predicting blood-brain barrier partitioning of organic molecules using membrane-interaction QSAR analysis. Pharm Res 2002;19:1611-21 (Pubitemid 35305512)
132. Konovalov DA, Coomans D, Deconinck E, Heyden YV. enchmarking of QSAR models for blood-brain barrier permeation. J Chem Inf Model 2007;47:1648-56 (Pubitemid 47210068)
133. Gozalbes R, Pineda-Lucena A. QSAR-based solubility model for drug-like compounds. Bioorg Med Chem 2010;18:7078-84
134. Hewitt M, Cronin MT, Madden JC, et al. Consensus QSAR models: do the benefits outweigh the complexity? J Chem Inf Model 2007;47:1460-8 (Pubitemid 47210049)
135. Swiss Institute for Bioinformatics. Available from: http://www. click2drug-org/directory-ADMET.html; Cited
136. Varma-o'brien S. Deliver on the 'fail early' pharmaceutical mantra. R D Dir 2009;15:10-11
137. Subramaniam S, Mehrotra M, Gupta D. Virtual high throughput screening (vHTS)-a perspective. Bioinformation 2008;3:14-17
138. Renier C, Faraco JH, Bourgin P, et al. Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. Pharmacogenet Genomics 2007;17:237-53 (Pubitemid 46668048)